SK Life Science, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 2002-01-01

Employees: 101

Market Cap: -

Website: http://www.sklifescienceinc.com

Clinical Trials

Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

Phase 4

Recruiting

Conditions: Focal Onset Seizure

Interventions: Drug: Cenobamate

First Posted Date: 2024-06-11

Last Posted Date: 2024-11-28

Lead Sponsor: SK Life Science, Inc.

Target Recruit Count: 90

Registration Number: NCT06453213

Locations: 🇺🇸
Arizona Neuroscience Research, Phoenix, Arizona, United States
🇺🇸
Center For Neurosciences, Tucson, Arizona, United States
🇺🇸
Clinical Trials Inc, Little Rock, Arkansas, United States

and more 37 locations

A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 mg Cenobamate Administered Orally

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Cenobamate

First Posted Date: 2022-10-07

Last Posted Date: 2023-05-10

Lead Sponsor: SK Life Science, Inc.

Target Recruit Count: 24

Registration Number: NCT05572255

Locations: 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States

Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

Phase 1

Terminated

Conditions: Advanced Solid Tumor

Interventions: Drug: SKL27969

First Posted Date: 2022-05-24

Last Posted Date: 2024-04-02

Lead Sponsor: SK Life Science, Inc.

Target Recruit Count: 17

Registration Number: NCT05388435

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Carolina BioOncology Institute, Huntersville, North Carolina, United States
🇺🇸
START Midwest, Grand Rapids, Michigan, United States

and more 1 locations

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

Phase 3

Recruiting

Conditions: Lennox Gastaut Syndrome
Seizures

Interventions: Drug: Carisbamate

First Posted Date: 2022-02-02

Last Posted Date: 2024-05-06

Lead Sponsor: SK Life Science, Inc.

Target Recruit Count: 252

Registration Number: NCT05219617

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇮🇱
Soroka University Medical Centre, Be'er Sheva, Israel
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

and more 66 locations

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age with Partial-onset (focal) Seizures

Phase 3

Recruiting

Conditions: Partial Epilepsy

Interventions: Drug: Xcopri

First Posted Date: 2021-10-05

Last Posted Date: 2024-12-19

Lead Sponsor: SK Life Science, Inc.

Target Recruit Count: 140

Registration Number: NCT05067634

Locations: 🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States

and more 51 locations

Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-Onset Seizures

Phase 1

Recruiting

Conditions: Partial Epilepsy

Interventions: Drug: Xcopri

First Posted Date: 2021-05-26

Last Posted Date: 2024-12-20

Lead Sponsor: SK Life Science, Inc.

Target Recruit Count: 24

Registration Number: NCT04903314

Locations: 🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland, United States

and more 8 locations

Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Cenobamate

First Posted Date: 2021-03-10

Last Posted Date: 2024-03-28

Lead Sponsor: SK Life Science, Inc.

Target Recruit Count: 15

Registration Number: NCT04791553

Locations: 🇸🇰
Summit Clinical Research s.r.o., Bratislava, Slovakia
🇵🇱
Centrum Badan Klinicznych Piotr Napora lekarze sp.p.,, Wrocław, Poland

Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cenobamate 200Mg Tab Fasted
Drug: Cenobomate Oral Suspension Fasted
Drug: Cenobamate Oral Suspension Fed

First Posted Date: 2020-12-31

Last Posted Date: 2024-08-12

Lead Sponsor: SK Life Science, Inc.

Target Recruit Count: 28

Registration Number: NCT04690751

Locations: 🇺🇸
PRA Health Sciences Salt Lake City, Millcreek, Utah, United States

Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS

Phase 3

Active, not recruiting

Conditions: Partial Seizure
Focal Seizure

Interventions: Drug: Placebo
Drug: Cenobamate

First Posted Date: 2020-09-21

Last Posted Date: 2023-10-10

Lead Sponsor: SK Life Science, Inc.

Target Recruit Count: 540

Registration Number: NCT04557085

Locations: 🇨🇳
Site 3, Shanghai, China
🇯🇵
Site 2, Tokyo, Japan
🇰🇷
Site 1, Seoul, Korea, Republic of

Bioavailability and Food Effect Study of 3 Types of Carisbamate

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Carisbamate

First Posted Date: 2020-08-20

Last Posted Date: 2021-10-07

Lead Sponsor: SK Life Science, Inc.

Target Recruit Count: 33

Registration Number: NCT04520360

Locations: 🇺🇸
PRA Health Sciences- Salt Lake City, Salt Lake City, Utah, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy